The Hormonal Transdermal Patches market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Hormonal Transdermal Patches market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Contraceptive Patches
Estradiol Patches
Others
Market segment by Application can be divided into
Hospital
Clinic
The key market players for global Hormonal Transdermal Patches market are listed below:
Xulane
Twirla
Planned Parenthood
Lvye Pharma
Novartis
Bayer Healthcare Pharmaceuticals
Watson Labs
Women First Healthcare Inc
Noven
AbbVie
Lumara Health
ANI Pharmaceuticals
Market segment by Region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 14 chapters:
Chapter 1, to describe Hormonal Transdermal Patches product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Hormonal Transdermal Patches, with price, sales, revenue and global market share of Hormonal Transdermal Patches from 2019 to 2021.
Chapter 3, the Hormonal Transdermal Patches competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Hormonal Transdermal Patches breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2016 to 2026.
Chapter 5 and 6, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2016 to 2026.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2016 to 2021.and Hormonal Transdermal Patches market forecast, by regions, type and application, with sales and revenue, from 2021 to 2026.
Chapter 12, 13 and 14, to describe Hormonal Transdermal Patches sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Hormonal Transdermal Patches Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Hormonal Transdermal Patches Revenue by Type: 2019 Versus 2021 Versus 2026
1.2.2 Contraceptive Patches
1.2.3 Estradiol Patches
1.2.4 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Hormonal Transdermal Patches Revenue by Application: 2019 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Hormonal Transdermal Patches Market Size & Forecast
1.4.1 Global Hormonal Transdermal Patches Sales in Value (2016-2026))
1.4.2 Global Hormonal Transdermal Patches Sales in Volume (2016-2026)
1.4.3 Global Hormonal Transdermal Patches Price by Type (2016-2026) & (US$/Unit)
1.5 Global Hormonal Transdermal Patches Production Capacity Analysis
1.5.1 Global Hormonal Transdermal Patches Total Production Capacity (2016-2026)
1.5.2 Global Hormonal Transdermal Patches Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Hormonal Transdermal Patches Market Drivers
1.6.2 Hormonal Transdermal Patches Market Restraints
1.6.3 Hormonal Transdermal Patches Trends Analysis
2 Manufacturers Profiles
2.1 Xulane
2.1.1 Xulane Details
2.1.2 Xulane Major Business
2.1.3 Xulane Hormonal Transdermal Patches Product and Services
2.1.4 Xulane Hormonal Transdermal Patches Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.2 Twirla
2.2.1 Twirla Details
2.2.2 Twirla Major Business
2.2.3 Twirla Hormonal Transdermal Patches Product and Services
2.2.4 Twirla Hormonal Transdermal Patches Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.3 Planned Parenthood
2.3.1 Planned Parenthood Details
2.3.2 Planned Parenthood Major Business
2.3.3 Planned Parenthood Hormonal Transdermal Patches Product and Services
2.3.4 Planned Parenthood Hormonal Transdermal Patches Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.4 Lvye Pharma
2.4.1 Lvye Pharma Details
2.4.2 Lvye Pharma Major Business
2.4.3 Lvye Pharma Hormonal Transdermal Patches Product and Services
2.4.4 Lvye Pharma Hormonal Transdermal Patches Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.5 Novartis
2.5.1 Novartis Details
2.5.2 Novartis Major Business
2.5.3 Novartis Hormonal Transdermal Patches Product and Services
2.5.4 Novartis Hormonal Transdermal Patches Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.6 Bayer Healthcare Pharmaceuticals
2.6.1 Bayer Healthcare Pharmaceuticals Details
2.6.2 Bayer Healthcare Pharmaceuticals Major Business
2.6.3 Bayer Healthcare Pharmaceuticals Hormonal Transdermal Patches Product and Services
2.6.4 Bayer Healthcare Pharmaceuticals Hormonal Transdermal Patches Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.7 Watson Labs
2.7.1 Watson Labs Details
2.7.2 Watson Labs Major Business
2.7.3 Watson Labs Hormonal Transdermal Patches Product and Services
2.7.4 Watson Labs Hormonal Transdermal Patches Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.8 Women First Healthcare Inc
2.8.1 Women First Healthcare Inc Details
2.8.2 Women First Healthcare Inc Major Business
2.8.3 Women First Healthcare Inc Hormonal Transdermal Patches Product and Services
2.8.4 Women First Healthcare Inc Hormonal Transdermal Patches Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.9 Noven
2.9.1 Noven Details
2.9.2 Noven Major Business
2.9.3 Noven Hormonal Transdermal Patches Product and Services
2.9.4 Noven Hormonal Transdermal Patches Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.10 AbbVie
2.10.1 AbbVie Details
2.10.2 AbbVie Major Business
2.10.3 AbbVie Hormonal Transdermal Patches Product and Services
2.10.4 AbbVie Hormonal Transdermal Patches Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.11 Lumara Health
2.11.1 Lumara Health Details
2.11.2 Lumara Health Major Business
2.11.3 Lumara Health Hormonal Transdermal Patches Product and Services
2.11.4 Lumara Health Hormonal Transdermal Patches Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
2.12 ANI Pharmaceuticals
2.12.1 ANI Pharmaceuticals Details
2.12.2 ANI Pharmaceuticals Major Business
2.12.3 ANI Pharmaceuticals Hormonal Transdermal Patches Product and Services
2.12.4 ANI Pharmaceuticals Hormonal Transdermal Patches Sales, Price, Revenue, Gross Margin and Market Share (2019-2021)
..…..continued
CONTACT DETAILS :
+44 203 500 2763
+1 62 825 80070
971 0503084105
The growth of the market is attributed favorable reimbursement scenario and strong government support in selected countries, technological advancements in insulin delivery devices, and growing diabetic population.
Increasing research and development activities and increase in diabetes-related health expenditure in emerging economies are expected to offer significant growth opportunities for manufacturers in the coming years.The Insulin Delivery Devices Market is expected to reach USD 17.8 billion by 2021 from USD 11.5 billion in 2016, at a CAGR of 9.1% during the forecast period.Ask for PDF Brochure :- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=107632092Key Market Drivers:- 1 Growing Diabetic Population 2 Technological Advancements in Insulin Delivery Devices 3 Favorable Reimbursement Environment and Government Support in Selected Countries 4 Conferences, Meetings, and Congresses to Create Awareness About Insulin Delivery DevicesMarket Segmentation:-Based on type, the insulin delivery devices market is categorized into pens, pumps, pen needles, syringes, and others (insulin inhalers, transdermal patches, and insulin jet injectors, among others).
In 2016, the pens segment is expected to command the largest share of the insulin delivery devices market.
The pens segment is further divided into reusable and disposable pens.
The reusable pens segment is estimated to command the largest share of the insulin pens market in 2016.
This large share can be attributed to lower price compared to disposable pens; availability of reimbursement in selected countries, and increasing adoption of insulin pens in the Asia-Pacific region.By end user, the insulin delivery devices market is segmented into patients/homecare and hospitals & clinics.
Global Insulin Delivery Devices (Idd) Market Size, Application And Trends Analysis By Type (Insulin Syringes, Pen, Insulin Pumps, Insulin Jet Injectors, Pen Needles And Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Sales And Diabetes Clinics/ Centers), End User (Hospitals & Clinics, Homecare And Specialty Centres) And Region (Americas, Europe, Asia-Pacific And Middle East & Africa) - Forecast Till 2025Global Market - OverviewThe insulin delivery devices market is growing at a rapid pace; mainly due to the rapidly increasing number of diabetic populations.
Insulin delivery devices are adaptable & lifestyle friendly, and hence these are garnering huge popularity and advancement due to its programmable physiologic technique for the delivery of insulin.The current research and development activities that are coordinating the two technologies, "sensor-augmented" and "sensor-driven" to develop pumps with completely automated & independent sensing and delivery system are expected to escalate the market on the ascending global heights.Acknowledging the burnished growth, the market perceives currently, Market Research Future (MRFR) in its recently published study report asserts that the global insulin delivery devices market is expected to accrue exponentially by 2020, registering 7.9 % CAGR between 2014 and 2020.
Additional factors fostering the growth of this market include the rise in the obese population, the prevalence of diabetes that is rising significantly, and the spreading awareness towards diabetic care, worldwide.
Thus, if these trends linearly continue over the next couple of years, it will dramatically increase the number of populations diagnosed with diabetes which, in turn, will substantially foster the demand for insulin delivery devices.With the rising number of diabetic patients, the demand for insulin delivery devices is expected to surge, thus resulting in exploding the size of the global insulin pumps market.Global Insulin Delivery Devices Market - SegmentsThe MRFR analysis is segmented into two key dynamics for the convenience of understanding;By Type : Insulin Syringe, Insulin Pumps, Insulin Pens, Insulin Jet Injectors and others (jet injectors, transdermal patches, and inhalers).By Regions: Europe, North America, Asia Pacific, and the Rest-of-the-World (RoW).Global Insulin Delivery Devices Market - Competitive LandscapeThe rapidly growing market of insulin delivery devices appears fiercely competitive and fragmented with many large and small-scale players alongside new entrants forming a competitive landscape.
The fierce competition in the anti-diabetic drug market has forced many players to developed delivery devices as an effective way to control the fall in revenues.Matured players are increasingly seeking market expansion through various strategic initiatives such as mergers and acquisitions, increasing investments, innovation, and R to develop cost-effective product portfolio.
The partnership formed are helping the companies to reduce the development costs associated with the insulin delivery devices.These players possess state-of-the-art developing labs and strong sales and distribution network that can help them to gain the leadership position in the market.
It is a system that offers continuous delivery of drug or medication in predictable and reproducible kinetics throughout the course of gastrointestinal transit.
The global controlled release drug delivery market, as per a report by Market Research Future (MRFR) is touted to register a CAGR of 14.0%, surpassing a valuation of USD 70.15 billion during the forecast period (2018-2023).Controlled release drug delivery system offers several benefits like lower dose requirement, improved stability of the drug, enhanced drug safety and efficacy, minimum side effects, improved patient compliance, and higher bioavailability.
This system also allows dose reduction, which minimizes the risk of overdose, especially in the aging population.
The unpleasant taste of dysphagia or pediatric medication for aging population will elevate the scope of the market in the long run.On the contrary, strict government policies and complex manufacturing process are some of the concerns likely to vitiate the market growth across the globe.Controlled Release Drug Delivery Market: Segmental AnalysisThe controlled release drug delivery market has been segmented on the basis of products, release mechanism, route of administration, and end users.By products, the controlled release drug delivery market is segmented into needle-free injectors, metered-dose inhalers, nasal sprays, auto-injectors, nebulizers, transdermal patches, drug-eluting stents, infusion pumps, ocular implants, and sustained release.The route of administration segment comprises injectable, oral, nasal, ocular, topical, and implantable.
Moreover, better patient compliance, flexibility, and reduced dosing frequency are likely to contribute to the market growth in the segment.
Rising research and development activities, advanced infrastructure in the pharmaceutical industry, and the existence of robust pharmaceutical companies in North America will encourage the market growth.Europe has managed to seize the second-largest share in the global market due to the increased incidence of respiratory diseases and hypertension among individuals.
